JP2022505388A - 5-ht4受容体アゴニストの新しい使用 - Google Patents

5-ht4受容体アゴニストの新しい使用 Download PDF

Info

Publication number
JP2022505388A
JP2022505388A JP2021521392A JP2021521392A JP2022505388A JP 2022505388 A JP2022505388 A JP 2022505388A JP 2021521392 A JP2021521392 A JP 2021521392A JP 2021521392 A JP2021521392 A JP 2021521392A JP 2022505388 A JP2022505388 A JP 2022505388A
Authority
JP
Japan
Prior art keywords
disease
dementia
alzheimer
parkinson
methoxypropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021521392A
Other languages
English (en)
Japanese (ja)
Inventor
ラーマクリシュナ・ニロギ
アブドゥル・ラシード・モハメッド
アニル・カルバーリ・シンデ
ヴェンカタ・ラマリンガッヤ・グランディ
プラディープ・ジャヤラジャン
ヴィジェイ・ベナデ
ゴピナーダ・バイラプネニ
ヴェンカテスワール・ジャスティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suven Life Sciences Ltd
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of JP2022505388A publication Critical patent/JP2022505388A/ja
Priority to JP2023032962A priority Critical patent/JP2023060148A/ja
Priority to JP2023032963A priority patent/JP2023060149A/ja
Priority to JP2023032961A priority patent/JP2023060147A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021521392A 2018-10-18 2019-10-17 5-ht4受容体アゴニストの新しい使用 Pending JP2022505388A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023032962A JP2023060148A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用
JP2023032963A JP2023060149A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用
JP2023032961A JP2023060147A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841039516 2018-10-18
IN201841039516 2018-10-18
PCT/IB2019/058853 WO2020079630A1 (en) 2018-10-18 2019-10-17 New uses of a 5-ht4 receptor agonist

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2023032961A Division JP2023060147A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用
JP2023032962A Division JP2023060148A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用
JP2023032963A Division JP2023060149A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用

Publications (1)

Publication Number Publication Date
JP2022505388A true JP2022505388A (ja) 2022-01-14

Family

ID=68470571

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021521392A Pending JP2022505388A (ja) 2018-10-18 2019-10-17 5-ht4受容体アゴニストの新しい使用
JP2023032963A Pending JP2023060149A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用
JP2023032961A Pending JP2023060147A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用
JP2023032962A Pending JP2023060148A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023032963A Pending JP2023060149A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用
JP2023032961A Pending JP2023060147A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用
JP2023032962A Pending JP2023060148A (ja) 2018-10-18 2023-03-03 5-ht4受容体アゴニストの新しい使用

Country Status (15)

Country Link
US (3) US20210386727A1 (ko)
EP (1) EP3866800A1 (ko)
JP (4) JP2022505388A (ko)
KR (2) KR20230155613A (ko)
CN (1) CN113164465A (ko)
AU (2) AU2019361359B2 (ko)
BR (1) BR112021007365A2 (ko)
CA (1) CA3116650C (ko)
EA (1) EA202191044A1 (ko)
IL (1) IL282364A (ko)
MA (1) MA53918A (ko)
MX (1) MX2021004473A (ko)
NZ (1) NZ775671A (ko)
WO (1) WO2020079630A1 (ko)
ZA (1) ZA202102512B (ko)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509320A (ja) * 2011-09-19 2014-04-17 スヴェン・ライフ・サイエンシズ・リミテッド 5−ht4受容体リガンドとしてのヘテロアリール化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014404001B2 (en) 2014-08-16 2017-12-14 Suven Life Sciences Limited Process for large scale production of 1-isopropyl-3-{5- [1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}- 1h-indazole oxalate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509320A (ja) * 2011-09-19 2014-04-17 スヴェン・ライフ・サイエンシズ・リミテッド 5−ht4受容体リガンドとしてのヘテロアリール化合物

Also Published As

Publication number Publication date
KR20230155613A (ko) 2023-11-10
CA3116650A1 (en) 2020-04-23
US20240277690A1 (en) 2024-08-22
EP3866800A1 (en) 2021-08-25
ZA202102512B (en) 2024-06-26
JP2023060149A (ja) 2023-04-27
US20240293389A1 (en) 2024-09-05
CN113164465A (zh) 2021-07-23
AU2019361359A1 (en) 2021-05-20
IL282364A (en) 2021-06-30
US20210386727A1 (en) 2021-12-16
JP2023060148A (ja) 2023-04-27
AU2023201908A1 (en) 2023-05-04
CA3116650C (en) 2023-08-22
JP2023060147A (ja) 2023-04-27
AU2019361359B2 (en) 2023-04-20
EA202191044A1 (ru) 2021-07-13
BR112021007365A2 (pt) 2021-07-20
MX2021004473A (es) 2021-08-24
NZ775671A (en) 2024-07-26
KR20210076106A (ko) 2021-06-23
WO2020079630A1 (en) 2020-04-23
MA53918A (fr) 2022-01-26

Similar Documents

Publication Publication Date Title
US20150322049A1 (en) Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
JP6959371B2 (ja) 純粋な5−ht6受容体アンタゴニストの新たな使用
JP6606298B2 (ja) 純粋な5−ht6受容体アンタゴニストのnmda受容体アンタゴニストとの組合せ
JP6629464B2 (ja) 純粋な5−ht6受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びnmda受容体アンタゴニストの3種類の組合せ
JP2022505388A (ja) 5-ht4受容体アゴニストの新しい使用
EA047954B1 (ru) Новые применения 5-ht4 рецепторного агониста
EA045076B1 (ru) Новые применения 5-ht4 рецепторного агониста
CN114761008B (zh) 用于在患有痴呆的患者中治疗行为和心理症状的方法
JP2024156953A (ja) 認知症患者における行動・心理症状を治療するための方法
EA047219B1 (ru) Способы лечения поведенческих и психологических симптомов у пациентов с деменцией

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230626